NCT07155031View on ClinicalTrials.gov

Biotin-Acridine Red Cell Exchange Kinetics

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 15, 2026

Conditions

Sickle Cell Disease

Interventions

DEVICE

Pathogen reduced red blood cells

pathogen reduced red blood cells with biotin labeled aliquots will be transfused as part of routine care red cell exchange procedures

Sponsors

Lead Sponsor

Cerus Corporation

All Listed Sponsors

lead

Cerus Corporation

INDUSTRY

NCT07155031 - Biotin-Acridine Red Cell Exchange Kinetics | Biotech Hunter | Biotech Hunter